KFDA granted sale of Symbicort Smart.

Published: 2006-11-02 06:57:00

Updated: 2006-11-02 06:57:00

AstraZeneca Korea has received a KFDA approval for the sales of Symbicort (budesonide/formoterol), a combination of an inhaled corticosteroid and long-acting bronchodilator, for the treatment of asthma and Chronic Obstructive Pulmonary Disease (COPD), which has shown to be a more effective treatm...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK